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A B S T R A C T
Introduction. Results from a previous study showed that sexuality was negatively affected in females with untreated
obstructive sleep apnea (OSA). Data are sparse on the long-term effects of nocturnal continuous positive airway
pressure (CPAP) treatment on sexual difﬁculties and sexual distress in female patients with OSA.
Aim. The aim of the present study was to investigate the effects after 1 year of CPAP treatment on sexual difﬁculties,
sexual distress, and manifest sexual dysfunction in female patients with OSA. The effect of CPAP on life satisfaction
was also investigated.
Methods. Fifty-four therapy-compliant, female patients (age 22–71) received a survey before and after 1 year of
nocturnal CPAP treatment. The questions on this survey were drawn from three self-administered questionnaires:
two on sexuality and one on life satisfaction. The results were compared with a population sample. The Epworth
Sleepiness Scale was used for assessment of daytime sleepiness.
Main Outcome Measures. The Female Sexual Function Index, Female Sexual Distress Scale, Manifest Female
Sexual Dysfunction, four questions from Life Satisfaction 11, and the Epworth Sleepiness Scale were all used to
measure outcome.
Results. In total, 44 patients responded to the survey (81% response rate). The results were a signiﬁcant, positive
change in manifest female sexual dysfunction, but no signiﬁcant changes in isolated sexual difﬁculties or sexual
distress. Daytime sleepiness signiﬁcantly decreased after 1 year. The results from the Life Satisfaction 11 question-
naire remained unchanged after 1 year.
Conclusions. After 1 year of CPAP treatment, female patients with OSA reported reduced manifest sexual dysfunc-
tion. However, it cannot be concluded if this result is due to CPAP treatment alone. Furthermore, reduced daytime
tiredness was found in the surveyed population. CPAP treatment, per se, does not seem to affect partner relation-
ships. Petersen M, Kristensen E, Berg S, and Midgren B. Long-term effects of continuous positive airway
pressure treatment on sexuality in female patients with obstructive sleep apnea. Sex Med 2013;1:62–68.
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Introduction
Obstructive sleep apnea (OSA) is characterizedby repetitive partial or complete cessation of
breathing (hypopnea/apnea) during sleep due to
upper airway collapse. OSA may cause sleep frag-
mentation and daytime tiredness, increases cardio-
vascular morbidity and mortality, and negatively
affects neurocognitive function [1]. Treatment of
OSA with continuous positive airway pressure
(CPAP) has been shown to reduce these negative
effects [2–4]. Furthermore, OSA has been shown to
be associated with sexual dysfunction in males, and
studies on the effects of CPAP treatment generally
suggest a beneﬁcial effect on male sexuality.
Studies focusing on sexual function in female
patients with OSA are rare [5–8]. A search of
PubMed showed a lack of studies investigating
changes in both sexual function and sexual distress
in women after long-term CPAP treatment. A pre-
vious study found that many aspects of sexuality
in women with untreated OSA are negatively
affected, as compared with a female normative
group, even when confounders, such as age and
obesity, were taken into account [5]. The use of
psychoactive medication was associated with a
higher risk for sexual difﬁculties, sexual distress,
and manifest female sexual dysfunction. These
ﬁndings are consistent with the hypothesis that
female sexual distress is characterized by mental,
rather than physical, problems with sexuality, and is
not necessarily only linked to sexual dysfunction
but also to individual expectations [9,10].
Results from a long-term study of male OSA
patients showed a signiﬁcant improvement in
sexual function after 1 year ofCPAP treatment [11].
The aim of the present study was to investigate the
effects of 1 year of CPAP treatment on sexual
difﬁculties, sexual distress, and manifest sexual dys-
function in female OSA patients. Furthermore,
effects on life satisfaction were also investigated. It
was hypothesized that female patients with OSA
would report improved sexual life and decreased
daytime sleepiness after 1 year of CPAP treatment.
Material and Methods
Theprimary cohort of 92 female patients withOSA
was consecutively recruited from October 2005 to
January 2008 [5]. Only patients withOSA, who had
been recommended for CPAP treatment by an
experienced specialist, who were more than 18
years old, and could read and write Danish were
included in the study. Exclusion criteria were
comorbid sleep disorders and psychiatric condi-
tions. Obesity, depression, diabetes, and/or cardio-
vascular disorders were not criteria for exclusion.
Informed consent was obtained, and the study
was reviewed and approved by the local ethical
committee. Female participants from a cross-
sectional, national survey of Danish women’s
sexual life were used as controls. A total of 1,996
Danish women were identiﬁed from the central
health registry. Selection criteria were age 20–
65 years and zip codes, which ensured that the
group reﬂected the population regarding the part
of the country in which they lived. The women
were mailed the questionnaires. Two hundred
forty age-matched women were selected as the
control group to the OSA group—three from the
control group for each OSA patient. Data on age,
body mass index (BMI), permanent sexual rela-
tionship, and education were collected for both
patients and normal subjects.
The two questionnaires on sexuality in women
were the following: (i) The Female Sexual Func-
tion Index (FSFI) (Appendix S1), which is only for
women with partners [12], scores ranging 2–36,
where a total score cutoff of ≤26.55 indicates
sexual difﬁculties [13]; (ii) the Female Sexual Dis-
tress Scale (FSDS) (Appendix S2) [14], scores
ranging 0–72, where a total score cutoff of ≥15
indicates sexual distress. Furthermore, The Mani-
fest Female Sexual Dysfunction (MFSD) [15,16]
was used, which is a combined index from the
cutoff scores in FSFI (≤26.55) and FSDS (≥15),
indicating that both sexual difﬁculties and sexual
distress are present. MFSD has not been validated
but is described and tested by Oberg et al. [15].
Four questions (life as a whole, family life, rela-
tionship to partner, and sexual life) were selected
from the questionnaire, Life Satisfaction 11
(LiSat-11) (Appendix S3) [17], after consultation
with the author (Dr. A. Fugl-Meyer, pers. comm.),
each score ranging 1–6. The Epworth Sleepiness
Scale (ESS) (Appendix S4) assesses the likelihood
of the patient to doze off or fall asleep in eight
daily situations, using a score between 0 and 3,
score ranging 0–24, and has a cutoff of ≥10, which
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indicates daytime sleepiness [18,19]. After 1 year
of CPAP treatment, questionnaires were given to
those OSA patients who were still using CPAP. To
ensure anonymity, the questionnaires were coded
in order to retrieve baseline data for each patient,
but the coding did not reveal the identity of the
patient. Thus, reminders could not be sent.
Menopause was considered a relevant variable,
but since the state of menopause was not known
for all subjects, the data were subdivided according
to age, with a cutoff value of 45 years as a proxy for
menopause.
All patients were investigated for OSA using
identical, portable devices (EMBLETTA, Embla,
Broomﬁeld, CO, USA). The recording montage
included nasal airﬂow and snoring, using a nasal
pressure catheter, respiratory movement with tho-
racic and abdominal bands (XactTrace, Embla,
Broomﬁeld, CO, USA), pulse oximetry, and body
position. Apneas were diagnosed as the cessation of
breathing of >10 seconds. Hypopneas were diag-
nosed as the reduction in airﬂow >30%, associated
with a desaturation of ≥4%. The apnea and
hypopnea index (AHI) was calculated as the total
number of apneas and hypopneas, divided by the
estimated sleep time, in hours. AHI 5–15 is consid-
eredmild sleep apnea, AHI 15–30 ismoderate sleep
apnea, and AHI >30 is severe sleep apnea. Patients,
who, after 1 year, had used their CPAP for less than
an average of 4 hours/night were considered non-
compliant to CPAP treatment, and excluded.
Statistical Analysis
Descriptive statistics (mean and standard deviation
[SD]) were used to summarize the clinical and
sociodemographic data. Paired t-tests were used
when comparing numerical study data before and
during CPAP treatment. The McNemar’s test (for
changes in proportion of categorical data) was used
when investigating the changes in FSFI (cutoff
≤26.55), FSDS (cutoff ≥15), and MFSD. Pearson’s
correlation analysis was used to relate age
(≥45 years), BMI (≥30), ESS, FSFI, FSDS, and
LiSat-11. All tests were performed on the whole
group, as well as on each subgroup, divided into
two: <45 years old and ≥45 years old. A signiﬁcance
level of P < 0.05 was used for all statistical analyses.
Results
In total, 92 female patients, aged 22–71 years, were
included in the baseline study [5]. Of these, 54
(59%) continued to use CPAP after 1 year. These
patients were given the follow-up questionnaires.
Forty-four (81% response rate) patients returned
the forms. All of the respondents used their CPAP
for >4 hours/night, on average. AHI was not col-
lected after 1 year. Sociodemographic and medical
data in the respondent group and population
sample are shown in Table 1. Signiﬁcant correla-
tions were calculated between BMI (≥30) and age
(≥45 years), family life and BMI (≥30), life as a
whole and age (≥45 years), and life as a whole and
ESS. The 10 women who did not return the 1-year
evaluation questionnaires did not show any statis-
tically signiﬁcant differences in sociodemograph-
ics or most of their medical data, in comparison
with the responding 44 CPAP users. The only
differences that they showed were lower BMI
(28.4 ± 5.8 vs. 34.7 ± 7.9; P = 0.02) and lower ESS
(4.0 ± 1.0 vs. 11.0 ± 3.7; P = 0.003).
FSFI
Female Sexual Function Index only included
women with a regular partner (n = 32). Paired
t-tests showed no signiﬁcant improvements for any
of the components of FSFI: desire (P = 0.69),
arousal (P = 0.97), lubrication (P = 0.85), orgasm
(P = 0.90), satisfaction (P = 0.96), pain (P = 0.94) or
total score (P = 0.89) (Table 2). The proportion of
patients without sexual difﬁculties (FSFI ≤ 26.55)
did not improve signiﬁcantly (Figure 1). Splitting
the group into age < or ≥45 years showed no sub-
group effects.
FSDS
Female Sexual Distress Scale included 44 women.
Paired t-tests showed no signiﬁcant improvement
for FSDS (P = 0.06). Total scores are shown in
Table 2. The number of patients without sexual
distress (FSDS ≥ 15) did not improve signiﬁcantly
(Figure 1). Splitting the group into age <45 or ≥45
years showed no subgroup effects.
MFSD
Manifest Female Sexual Dysfunction included only
women with regular partner (n = 32). The propor-
tion of patients with MFSD (the secondary index
derived from FSFI and FSDS) was signiﬁcantly
lower after 1 year on CPAP treatment (Figure 1).
There was a tendency to a stronger effect in the
older (≥45 years) age group (P = 0.06) as compared
with the younger (<45 years) (P = 0.63).
LiSat-11
Paired t-tests showed no signiﬁcant improvements
for any of the tested parameters of the LiSat-11:
life as a whole (P = 0.59), family life (P = 0.73),
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partner relationship (P = 1.00), and sexual life
(P = 0.92). Splitting the group into age < or
≥45 years showed no subgroup effects.
ESS
Paired t-tests showed that ESS improved signiﬁ-
cantly after 1 year of CPAP treatment (P < 0.001)
(Table 1). The effect was present in both sub-
groups (<45 years P = 0.014 and ≥45 years;
P = 0.004).
Discussion
The main result from this study is that the previ-
ous observation of a beneﬁcial effect of CPAP on
Table 1 Anthropometric, social, and medical data in the population sample and in female patients with obstructive sleep
apnea at baseline, and after 1 year of CPAP treatment
Population
sample
Before CPAP After 1 year P values
Nonrespondents
to the survey
after 1 year
Respondents
to the survey
after 1 year
In CPAP
treatment
Before CPAP
nonrespondents
vs. respondents
Before vs.
after 1 year in
CPAP treatment
n 240 10 44 44 54 44
Age, mean (SD) 51.3 (8.8) 57.0 (7.5) 52.0 (10.9) NA 0.179* NA
Age ≥45, n (%) 182 (76) 9 (90) 31 (70) NA 0.263† NA
Having a sexual partner (%) 204 (85) 7 (70) 34 (77) 34 (77) 0.627† 1.000†
Education ≥10 years, n (%) 219 (91) 7 (70) 32 (82) NA 0.767† NA
Medication
Cardiovascular medication‡, n (%) 56 (23) 6 (60) 21 (48) NA 0.363† NA
Psychopharmaca§, n (%) 26 (11) 2 (20) 12 (27) NA 0.699† NA
Antidiabetics¶, n (%) 9 (4) 0 4 (9) NA 0.335† NA
BMI, mean (SD) 25.0 (4.3) 28.4 (5.8) 34.7 (7.9) 33.6 (6.3) 0.022* 0.307*
BMI range 18–46 23–39 23–64 23–47 NA NA
BMI ≥30, n (%) 29 (12) 3 (30) 31 (70) 26 (59) 0.019† 0.186†
AHI, mean (SD) NA 37.5 (21.6) 35.7 (25.3) NA 0.854* NA
ESS, mean (SD) NA 4.0 (1.0) 11.0 (3.7) 7.0 (4.3) 0.003* 0.000*
*Student’s t-test.
†χ2-test.
‡Digoxin, antihypertensive, diuretics, beta blockers, calcium antagonists, ACE inhibitors.
§Antipsychotics, anxiolytics, hypnotics, antidepressants.
¶Given orally or as injections.
NA = not analyzed; BMI = body mass index; AHI = apnea hypopnea index; ESS = Epworth Sleepiness Scale
Table 2 Scores of Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS) for women with
obstructive sleep apnea (OSA) at baseline, and after 1 year of CPAP treatment, with the population sample scores for
comparison
OSA, baseline OSA, 1 year
Population
sample
OSA baseline—
Population
sample
OSA baseline—
1 year
OSA 1 year—
Population
sample
P value P value P value
FSDS, total score mean (SD) 16.59 (12.23) 13.77 (11.37) 10.15 (10.07) <0.001 0.06 <0.05
FSFI, total score mean (SD) 20.34 (9.60) 20.94 (9.22) 24.36 (9.78) <0.05 0.89 <0.01
P values were calculated using the Student’s t-test.
30
∗
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Figure 1 Manifest Female Sexual
Dysfunction (MFSD), Female Sexual
Distress Scale (FSDS), and Female
Sexual Function Index (FSFI) scores
in female patients with obstructive
sleep apnea (OSA) before and after 1
year of CPAP treatment. MFSD scores
indicate that both sexual difficulties
and sexual distress are present
(n = 32). Score ≥15 in FSDS indicates
sexual distress (n = 44). Score ≤26.55
in FSFI indicates sexual difficulties
(n = 32).
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sexuality in males with OSA can also be extended
to females, although the effect seems to be less
pronounced [11].
The strength of this study is that it was sufﬁ-
ciently long to allow for adaptation to CPAP treat-
ment, which often takes at least a couple of
months. Many patients may be reluctant to use a
treatment involving the use of a mask, a tube, and
machine every night for many years to come.
However, one of the main ﬁndings is that CPAP
treatment, per se, does not negatively affect family
life or partner relationships. Sharing this informa-
tion with patients may be important when initiat-
ing CPAP treatment.
FSFI and FSDS did not change signiﬁcant after
1 year in CPAP treatment. MFSD demonstrated a
signiﬁcant improvement. However, it cannot be
concluded if this result is due to CPAP treatment.
Whereas men improved their sexuality in several
speciﬁc aspects [11], the effect in women could only
be demonstrated as an improvement of MFSD,
which is a composite measure indicating women
being sexual dysfunctional (measured by FSFI)
and having sexual distress (measured by FSDS).
Whether this result represents a true gender differ-
ence or if it is merely due to underpowering of our
study is a topic for further research.
ESS was used as a measure of sleepiness/
daytime tiredness. ESS improved signiﬁcantly,
indicating a positive effect on daytime tiredness.
The magnitude of this effect was similar for men
and women. AHI was not collected after 1 year,
but a decrease in ESS could be indicative of a
reduction in AHI. It is important to underline that
all patients in the study of male sexuality [11], as
well as in this study, underwent the same diagnos-
tic procedures, performed, and received the same
instructions, follow-up, and treatment contacts.
There were no signiﬁcant changes in the three
items investigating closeness in the LiSat-11
(family life, partner relationship, and sexual life).
However, in a previous study [5], results at baseline
showed no signiﬁcant differences in the untreated
OSA group compared with the normative group,
providing no indication that closeness is impaired
by OSA or necessarily impaired by its treatment by
CPAP. Thus, our results suggest that CPAP does
not cause changes in closeness.
The lack of validity of the MFSD is a limitation
of the study. The decision to use MFSD was taken
because it has been used meaningfully in other
studies and the deﬁnition that both sexual difﬁcul-
ties and sexual distress should be present before
talking about sexual dysfunction makes sense.
Conditions in one’s life can result in decreased
sexual function without necessarily meaning sexual
distress. Conversely, you can experience sexual dis-
tress without necessarily meaning decreased sexual
function. The signiﬁcant improvement in MFSD,
but not in FSFI and FSDS (though there was a
trend for FSDS), indicates that an Error 2 may
explain these differences. However, using the base-
line number of 80 participants for the analysis, the
result showed a signiﬁcant improvement in both
FSFI and FSDS. One might speculate that a
better-powered study would yield different ﬁnd-
ings. Gender differences may also explain the
results. A number of studies have shown that
gender has a signiﬁcant inﬂuence on sexuality, and
that there are marked differences in sexuality
between genders. Laumann et al. [20] found that
sexual problems were associated with physical
health among men more often than women.
Other studies have found that mood and mental
well-being impact female sexuality. In one study,
Hartmann et al. [21] found that life stressors, con-
textual factors, past sexuality, and mental health
problems are important predictors of low sexual
desire. In a large study, Colson et al. [22] found that
63%of thewomen reported decreased sexual desire
during periods of work-related stress. The main
causes for the absence of sexual activity were tired-
ness (43%) and no desire (21%). A national survey
in America found that the best predictors of sexual
distress were markers of low general emotional
well-being and emotional relationship with partner
during sexual activity [23]. A review by McCabe
et al. [24] showed that neither treatment with psy-
chotherapy alone nor medical intervention alone is
sufﬁcient to helpwomenwith low sexual desire, and
suggests that therapy should be supplemented with
a biopsychosocial approach.
It is well known that depression inﬂuences
female sexuality [25–28], and thismay contribute to
the ﬁndings in this study, in which 27% of partici-
pants were using psychotropic medications at base-
line. Similar results have been found for other
chronic illnesses. In a study of diabetes and sexual-
ity in women, Nowosielski et al. [29] showed
that “the role of partner-related factors and
the presence of depressive symptoms in sexual
functioning of women seem to be greater than
biological.” Giraldi et al. [30] found that sexual
dysfunction in womenwith diabetes is less linked to
organic factors and more to psychological factors.
Duncan et al. [31] investigated quality of sexual
function in women with hypertension; they
found that there were no statistically signiﬁcant
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differences in reported sexual functioning between
the medicated and unmedicated group. The same
results were found in a study of quality of life in
hypertensive patients, where no signiﬁcant differ-
ence was found between treated and untreated
women with hypertension [32]. Furthermore,
Cavalcante et al. [32] did not ﬁnd any relation to the
number and type of cardiovascularmedication with
the quality of sex life. These results are consistent
with the ﬁndings in this study. Despite the fact that
48%of participants used cardiovascularmedication
at baseline in this study, there was no correlation to
sexual dysfunction.
Conclusion
After 1 year of CPAP treatment, female patients
with OSA reported reduced manifest sexual dys-
function. However, it cannot be concluded if this
result is due to CPAP treatment alone. Further-
more, reduced daytime tiredness was found in the
surveyed population. CPAP treatment, per se, does
not seem to affect partner relationships. Sharing
these ﬁndings with patients may be important for
future CPAP users.
Corresponding Author: Marian Petersen, RN, DMsc,
The Neuroscience Centre, Rigshospital, Blegdamsvej 9,
2100 Ø Copenhagen, Denmark. Tel: +45 35458624;
Fax: +45 35453247; E-mail: marian.christin.petersen@
rh.regionh.dk
Conﬂict of Interest: Marian Petersen has no conﬂict of
interest. Ellids Kristensen has received honoraria from
Pﬁzer, Bristol-Myers Squibb, Eli Lilly, and Servier for
lectures, and from Eli Lilly for consultant commit-
ments. Søren Berg is one of the owners and managers of
ScanSleep, and has received honoraria from ResMed
Denmark and Sweden for lectures and consultant com-
mitments. Bengt Midgren has received honoraria
from Philips Respironics Sweden, ResMed Sweden,
Denmark, and Norway, and from BREAS Medical
Sweden for lectures and consultant commitments.
References
1 Al Lawati NM, Patel SR, Ayas NT. Epidemiology, risk factors,
and consequences of obstructive sleep apnea and short sleep
duration. Prog Cardiovasc Dis 2009;51:285–93.
2 El-Sherbini AM, Bediwy AS, El-Mitwalli A. Association
between obstructive sleep apnea (OSA) and depression and the
effect of continuous positive airway pressure (CPAP) treat-
ment. Neuropsychiatr Dis Treat 2011;7:715–21.
3 Antic NA, Catcheside P, Buchan C, Hensley M, Naughton
MT, Rowland S, Williamson B, Windler S, McEvoy RD. The
effect of CPAP in normalizing daytime sleepiness, quality of
life, and neurocognitive function in patients with moderate to
severe OSA. Sleep 2011;34:111–9.
4 Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term
effects of nasal continuous positive airway pressure therapy on
cardiovascular outcomes in sleep apnea syndrome. Chest
2005;127:2076–84.
5 Petersen M, Kristensen E, Berg S, Giraldi A, Midgren B.
Sexual function in female patients with obstructive sleep apnea.
J Sex Med 2011;8:2560–8.
6 Onem K, Erol B, Sanli O, Kadioglu P, Yalin AS, Canik U,
Cuhadaroglu C, Kadioglu A. Is sexual dysfunction in women
with obstructive sleep apnea-hypopnea syndrome associated
with the severity of the disease? A pilot study. J Sex Med
2008;5:2600–9.
7 Subramanian S, Bopparaju S, Desai A, Wiggins T, Rambaud
C, Surani S. Sexual dysfunction in women with obstructive
sleep apnea. Sleep Breath 2010;14:59–62.
8 Koseoglu N, Koseoglu H, Itil O, Oztura I, Baklan B, Ikiz AO,
Esen AA. Sexual function status in women with obstructive
sleep apnea syndrome. J Sex Med 2007;4:1352–7.
9 McCall K, Meston C. Differences between pre- and post-
menopausal women in cues for sexual desire. J Sex Med
2007;4:364–71.
10 Basson R, Rees P, Wang R, Montejo AL, Incrocci L. Sexual
function in chronic illness. J Sex Med 2010;7(1 Pt 2):374–88.
11 Petersen M, Kristensen E, Berg S, Midgren B. Sexual function
in male patients with obstructive sleep apnoea after 1 year of
CPAP treatment. Clin Respir J 2012. 2012 July 3. doi:10.1111/
j.1752-699X.2012.00307.x. [Epub ahead of print].
12 Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh
R, Ferguson D, D’Agostino R Jr. The Female Sexual Function
Index (FSFI): A multidimensional self-report instrument for
the assessment of female sexual function. J Sex Marital Ther
2000;26:191–208.
13 Wiegel M, Meston C, Rosen R. The Female Sexual Function
Index (FSFI): Cross-validation and development of clinical
cutoff scores. J Sex Marital Ther 2005;31:1–20.
14 Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The
Female Sexual Distress Scale (FSDS): Initial validation of a
standardized scale for assessment of sexually related personal
distress in women. J Sex Marital Ther 2002;28:317–30.
15 Oberg K, Fugl-Meyer AR, Fugl-Meyer KS. On categorization
and quantiﬁcation of women’s sexual dysfunctions: An epide-
miological approach. Int J Impot Res 2004;16:261–9.
16 Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum
toxin type A-a novel treatment for provoked vestibulodynia?
Results from a randomized, placebo controlled, double blinded
study. J Sex Med 2009;6:2523–37.
17 Fugl-Meyer AR, Melin R, Fugl-Meyer KS. Life satisfaction in
18- to 64-year-old Swedes: In relation to gender, age, partner
and immigrant status. J Rehabil Med 2002;34:239–46.
18 Johns MW. A new method for measuring daytime sleepiness:
The Epworth Sleepiness Scale. Sleep 1991;14:540–5.
19 Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK,
Lyon K, Smith PL, Schwartz AR, Redline S, Pack AI, Dinges
DF. An instrument to measure functional status outcomes for
disorders of excessive sleepiness. Sleep 1997;20:835–43.
20 Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C,
Moreira E, Wang T. Sexual problems among women and men
aged 40–80 y: Prevalence and correlates identiﬁed in the
Global Study of Sexual Attitudes and Behaviors. Int J Impot
Res 2005;17:39–57.
21 Hartmann U, Philippsohn S, Heiser K, Ruffer-Hesse C. Low
sexual desire in midlife and older women: Personality factors,
psychosocial development, present sexuality. Menopause
2004;11(6 Pt 2):726–40.
22 Colson MH, Lemaire A, Pinton P, Hamidi K, Klein P. Sexual
behaviors and mental perception, satisfaction and expectations
of sex life in men and women in France. J Sex Med 2006;3:121–
31.
CPAP and Sexual Function in Female OSA Patients 67
Sex Med 2013;1:62–68© 2013 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
23 Bancroft J, Loftus J, Long JS. Distress about sex: A national
survey of women in heterosexual relationships. Arch Sex Behav
2003;32:193–208.
24 McCabe M, Althof SE, Assalian P, Chevret-Measson M,
Leiblum SR, Simonelli C, Wylie K. Psychological and inter-
personal dimensions of sexual function and dysfunction. J Sex
Med 2010;7(1 Pt 2):327–36.
25 Fabre LF, Smith LC. The effect of major depression on sexual
function in women. J Sex Med 2012;9:231–9.
26 Tagliabue M, Gottero C, Zuffranieri M, Negro M, Carletto S,
Picci RL, Tomelini M, Bertaina S, Pucci E, Trento M, Ostacoli
L. Sexual function in women with type 1 diabetes matched
with a control group: Depressive and psychosocial aspects. J
Sex Med 2011;8:1694–700.
27 Lai CH. Major depressive disorder: Gender differences in
symptoms, life quality, and sexual function. J Clin
Psychopharmacol 2011;31:39–44.
28 Schnatz PF, Whitehurst SK, O’Sullivan DM. Sexual dysfunc-
tion, depression, and anxiety among patients of an inner-city
menopause clinic. J Womens Health (Larchmt) 2010;19:
1843–9.
29 Nowosielski K, Drosdzol A, Sipinski A, Kowalczyk R,
Skrzypulec V. Diabetes mellitus and sexuality—Does it really
matter? J Sex Med 2010;7(2 Pt 1):723–35.
30 Giraldi A, Kristensen E. Sexual dysfunction in women with
diabetes mellitus. J Sex Res 2010;47:199–211.
31 Duncan LE, Lewis C, Jenkins P, Pearson TA. Does hyperten-
sion and its pharmacotherapy affect the quality of sexual func-
tion in women? Am J Hypertens 2000;13(6 Pt 1):640–7.
32 Cavalcante MA, Bombig MT, Luna FB, Carvalho AC, Paola
AA, Povoa R. Quality of life of hypertensive patients treated at
an outpatient clinic. Arq Bras Cardiol 2007;89:245–50.
Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Appendix S1 The Female Sexual Function Index.
Appendix S2 The Female Sexual Distress Scale—Revised.
Appendix S3 The LiSat-11 checklist.
Appendix S4 Epworth Sleepiness Scale (ESS).
68 Petersen et al.
Sex Med 2013;1:62–68 © 2013 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
